about
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic StrategiesMultifunctional nanoparticles for brain tumor imaging and therapy.Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside.In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.Comparison of two nitroxide labile esters for delivering electron paramagnetic resonance probes into mouse brainBrainpeps: the blood-brain barrier peptide database.Electroacupuncture reduces injury to the blood-brain barrier following cerebral ischemia/ reperfusion injury.CNS Anticancer Drug Discovery and Development Conference White Paper.Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells.Glutathione metabolism and Parkinson's disease.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers.Anticholinergics for overactive bladder therapy: central nervous system effects.Regional expression of epithelial MDR1/P-glycoprotein in chronic rhinosinusitis with and without nasal polyposis.Strategies for drug delivery to the central nervous system by systemic route.Efflux proteins at the blood-brain barrier: review and bioinformatics analysis.Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglycerol-mediated transfer to the brain.Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination.P-glycoprotein functions as an immunomodulator in healthy human primary nasal epithelial cells.Drug transporters are altered in brain, liver and kidney of rats with chronic epilepsy induced by lithium-pilocarpine.Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier.P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier.Efflux of drugs and solutes from brain: the interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters.Oatp58Dc contributes to blood-brain barrier function by excluding organic anions from the Drosophila brain.
P2860
Q26747496-E4DA9F01-776C-4A3D-9B8A-D15FD7C6C4CBQ26865418-1E06AA35-4321-49B1-B53D-97C5CA8DF8FFQ31065446-652A2824-4DA9-41DE-888E-73DA3D19FB98Q33567329-92CE3CA8-C432-4E6E-B5B4-DF3043602EEDQ33985133-981602F0-3433-4FDD-AA1E-EF0ED97E7C29Q34086803-884C7BD2-9ED8-409F-872D-54E8B1CAFBAFQ34243408-D6BD01D9-EB7D-42A6-B130-5DFDC5B81996Q34311380-2C371E45-8B1C-4A6F-82EC-250D5FD3ED11Q36089590-E2A7DFB6-6406-46BC-AFF7-591C80C5BC13Q37046775-2AF516EE-5E80-483B-8CEE-686205E6F8FFQ37078480-B367884B-F946-4B6E-8D6B-64947F2E69ADQ37113947-EC68FEF3-E097-4F11-9FEE-305F3D371436Q37266286-C7C51954-9F94-46A2-9DF8-FAE7A823DC90Q37308322-E467246F-E9E6-4402-BED6-EA62E95B8D48Q37399563-8BCCCA91-A08F-4222-90C0-65D3710F8EACQ37798553-FB808E70-4399-45F2-BE70-E6F3BD4EA3D4Q37954372-63826D2B-B686-45CA-BA3C-B57C3FF25E59Q37973700-85A905A5-A613-4105-A918-B322D8198D9DQ38182668-8EFD317D-EC15-49CB-8FA5-9C4C4DAA9278Q39290800-99FF5893-EB5B-40D8-89A9-FDAE6DF2915BQ40060003-63FE68C2-CD7B-4D82-959F-A966AA7EDC55Q41943293-0AC116F2-53E4-46D6-98BF-29FBEFAF8E6DQ42101445-B1A56FD3-4FC1-4604-98C7-8918CA1D6C0FQ42661918-BEF77C99-7B78-44E2-B01C-EFFEA6651097Q43156419-BAA3DE40-E9A1-47BF-A039-872FBAC0750EQ43520262-28A41705-C0AD-4478-8CCC-88F1688020B9Q44998746-78CC2F58-1119-4114-A25B-B14366006E9AQ48114250-F9333AB0-09FB-4F28-BEA9-F5CABFE5A777Q48238618-E08A8376-62DC-4215-A5D6-CA3BF9D1340AQ48567276-805B1FA9-4A44-40C4-A473-F4471485E119Q50875549-D0D8F841-BC42-4BC2-BB80-3A4488530384
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Blood-brain barrier efflux transport.
@ast
Blood-brain barrier efflux transport.
@en
type
label
Blood-brain barrier efflux transport.
@ast
Blood-brain barrier efflux transport.
@en
prefLabel
Blood-brain barrier efflux transport.
@ast
Blood-brain barrier efflux transport.
@en
P356
P1476
Blood-brain barrier efflux transport.
@en
P2093
Gary M Pollack
Pamela L Golden
P304
P356
10.1002/JPS.10424
P407
P577
2003-09-01T00:00:00Z